Jim Baranski, Executive Director at Lung Cancer Foundation of America, shared on LinkedIn:
“This month, the FDA approved zidesamtinib for adults with ROS1-positive non-small cell lung cancer who had already progressed on a prior ROS1 inhibitor.
ROS1 alterations show up in only 1-2% of lung cancer cases – a small population. In the trial behind this approval, 44% of previously treated patients responded, and 69% had their disease under control a year later, including people with brain metastases and known resistance mutations.
Precision medicine requires precision science – and these results come from researchers being funded to ask a specific question about how one gene alteration behaves, rather than treating lung cancer as a single disease.
Exactly the kind of science Lung Cancer Foundation of America is built to help move forward.
What’s one specific question you want lung cancer research to answer?”
You can find this interesting:
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
